Hosted on MSN
Magazine: Big biopharma take on the ADC challenge
Antibody‑drug conjugates (ADCs) remain an area of extreme focus in the pharmaceuticals space, with the market projected to hit a $40bn valuation by 2040. However, technical hurdles in the field remain ...
The astronomical rise in popularity of GLP-1RAs in recent years has led to a shortage, prompting users to turn to compounders as an alternative to the likes of Novo Nordisk’s semaglutide ...
STOCKHOLM--(BUSINESS WIRE)--A new scientific article, published in the US journal Clinical Pharmacology in Drug Development, shows how Xspray Pharma's HyNap™ technology improves the bioavailability ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results